Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on cell and gene therapies for life-threatening genetic diseases. The company commercializes ZEVASKYN®, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder causing chronic wounds and fragile skin, which it manufactures at a cGMP facility and delivers through qualified treatment centers while generating revenue from patient treatments reimbursed by insurance and public programs. Beyond its flagship product, Abeona is advancing an AAV-based gene therapy pipeline targeting ophthalmic diseases using proprietary AIM™ capsid technology, and generates additional revenue through licensing partnerships and milestone payments on out-licensed programs in other therapeutic areas.